## **Core Concept**
The question revolves around the management of acute myocardial infarction (AMI) with thrombolytic therapy, specifically streptokinase, and identifying a complication that necessitates stopping the therapy. Thrombolytic therapy is used to dissolve occlusive coronary artery thrombi in eligible patients with AMI. Streptokinase is a commonly used thrombolytic agent.

## **Why the Correct Answer is Right**
The correct answer, , indicates the presence of significant bleeding, which is a major risk of thrombolytic therapy. Thrombolytic agents like streptokinase work by activating plasminogen to plasmin, which then breaks down fibrin clots. However, this process can also lead to systemic fibrinolysis, increasing the risk of bleeding. A significant increase in PT (Prothrombin Time) and aPTT (activated Partial Thromboplastin Time) along with evidence of bleeding would suggest that the patient is at high risk of further bleeding complications. Therefore, if there's evidence of active bleeding or a high risk of bleeding (such as significantly elevated PT/aPTT), the therapy should be stopped.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because while it might represent some form of abnormality, without specifics on what it entails, it's hard to directly refute. However, generally, isolated lab values without clinical context are less indicative of an immediate need to stop therapy compared to clinical signs of bleeding.
- **Option B:** This option is incorrect because, similar to option A, it lacks specificity. ECG changes could be due to the MI itself or other conditions and aren't a direct indicator to stop thrombolytic therapy unless they indicate a new, significant arrhythmia or ischemia that could be a complication of the therapy.
- **Option C:** This option is incorrect because while new onset of heart failure could complicate the clinical picture, it's not a direct indication to stop thrombolytic therapy immediately unless it's due to a complication like severe mitral regurgitation or a ventricular septal defect, which aren't specified here.

## **Clinical Pearl / High-Yield Fact**
A critical clinical pearl is that the risk of major bleeding with thrombolytic therapy, such as streptokinase, necessitates close monitoring for signs of bleeding. The presence of active bleeding or significantly elevated coagulation times (PT/aPTT) should prompt consideration to stop the infusion.

## **Correct Answer: D.**